Publications by authors named "Amy Olson"

Claim this Profile
R
Real-world clinical and economic outcomes associated with supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States.
Joseph Yang, Andrea Steffens, Lee Brekke, Amy Anderson, Gursimran Basra, Amy L Olson

BMC Pulm Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence Rate and Prevalence of Idiopathic Pulmonary Fibrosis in the United States 2017-2022.
Yanni Fan, Haikun Bao, Pratik Pimple, Amy L Olson, Steven D Nathan

Ann Am Thorac Soc· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: a retrospective administrative claims database analysis.
Joseph Yang, Michael A Head, Kevin D Schott, Hiangkiat Tan, Rachel Djaraher, Amy L Olson

Rheumatology (Oxford)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial.
Valeria Santibanez, Aditi Mathur, Jigna Zatakia, Nicole Ng, Michele Cohen, Amy Olson

BMJ Open Respir Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
Coralynn Sack, Daniel M Wojdyla, Maeve G MacMurdo, Amanda Gassett, Joel D Kaufman, Amy L Olson

Ann Am Thorac Soc· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry.
Hyun J Kim, Jeremy M Weber, Megan L Neely, Amy Hajari Case, Aiham H Jbeli, Amy L Olson

Lung· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States.
Joseph Yang, Andrea Steffens, Amy L Olson, Amy Anderson, Gursimran Basra

Respir Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease.
Rohit Aggarwal, Chester V Oddis, Daniel I Sullivan, Siamak Moghadam-Kia, Didem Saygin, Amy L Olson

BMC Pulm Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis.
L Jason Lobo, Yi Liu, Peide Li, Murali Ramaswamy, Aparna C Swaminathan, Amy L Olson

BMC Pulm Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proportion and predictors of FVC decline in patients with interstitial lung disease.
Maeve G Macmurdo, Xinge Ji, Pratik Pimple, Amy L Olson, Alex Milinovich

Respir Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients.
Mona Nili, Andrew J Epstein, Dominic Nunag, Amy Olson, Bijan J Borah

BMC Pulm Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
Mona Nili, Andrea Steffens, Amy Anderson, Lee Brekke, Mary Grace Johnson, Amy L Olson

J Manag Care Spec Pharm· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients.
Mona Nili, Andrew J Epstein, Dominic Nunag, Amy Olson, Bijan Borah

BMC Pulm Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Luca Richeldi, Carey C Thomson, Yoshikazu Inoue, Andrew G Nicholson, Amy L Olson

Am J Respir Crit Care Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
Amy L Olson, Nadine Hartmann, Padmaja Patnaik, Elizabeth M Garry, Rhonda L Bohn

Adv Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nurses' and nurse educators' experiences of a Pediatric Nursing Continuing Professional Development program in Rwanda.
Amy K Olson, Yolanda Babenko-Mould, Panagiota D Tryphonopoulos, Donatilla Mukamana, David F Cechetto

Int J Nurs Educ Scholarsh· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
Amy L Olson, Padmaja Patnaik, Nadine Hartmann, Rhonda L Bohn, Elizabeth M Garry

Adv Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
Amy Olson, Nadine Hartmann, Padmaja Patnaik, Laura Wallace, Rozsa Schlenker-Herceg

Adv Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of rheumatoid arthritis and the risk of developing interstitial lung disease.
Michael P Mohning, Isabelle Amigues, M Kristen Demoruelle, Evans R Fernández Pérez, Tristan J Huie, Amy L Olson

ERJ Open Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Amy L Olson, Toby M Maher, Valentina Acciai, Baher Mounir, Manuel Quaresma

Adv Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knowledge translation: A concept analysis.
Amy Olson, Abe Oudshoorn

Nurs Forum· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Marlies Wijsenbeek, Michael Kreuter, Amy Olson, Aryeh Fischer, Elisabeth Bendstrup

Curr Med Res Opin· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in Idiopathic Pulmonary Fibrosis-related Mortality in the United States: 2000-2017.
Erik P Dove, Amy L Olson, Marilyn K Glassberg

Am J Respir Crit Care Med· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.
Karina Raimundo, Joshua J Solomon, Amy L Olson, Amanda M Kong, Ashley L Cole

J Rheumatol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
Amy L Olson, Alex H Gifford, Naohiko Inase, Evans R Fernández Pérez, Takafumi Suda

Eur Respir Rev· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis